Drug Type Bispecific antibody |
Synonyms KA 3002, KA3002 |
Target |
Action agonists, inhibitors |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Preclinical | China | 15 Jan 2022 |